AMENDMENT DATED DECEMBER 19, 2003 TO PHARMACOGENOMICS AGREEMENT



 Exhibit 10.12 
  

			
	[GRAPHIC]	 	 555 Long Wharf Drive, 11th Floor
 New Haven, CT
06511
 Phone (203) 401-3330
 Fax (203) 401-3333


  
 December 19, 2003 
  
 Bayer Corporation 
 400 Morgan Lane 
 West Haven, CT 06516-4175 
 ATTN: Legal Department 
  

	 	RE:	Amendment to Pharmacogenomics Agreement dated January 12, 2001 

  
 Gentlemen: 
  
 Reference is hereby made to the Pharmacogenomics Agreement dated January 12, 2001 between Bayer Corporation and CuraGen Corporation, as amended to date (as so amended, the “Agreement”). Capitalized terms
used herein but not otherwise defined shall have the meanings ascribed to them in the Agreement. 
  
 WHEREAS, the Set-up Phase of the Agreement has been successfully completed and the Production Phase has commenced as of August 15, 2002; and 

 
 WHEREAS, Bayer wishes to reduce the minimum number of Predictive
Toxicogenomic Screens specified in Appendix B from [*****], which will increase the unit costs to CuraGen of providing such pharmacogenomic services; and 
  
 WHEREAS, the minimum financial obligation specified in section 5.00(c), which translates into [**************** 
 *************************************], does not change; and 
  
 WHEREAS, the decrease in spending on predictive Toxicogenomic Screen will be made up by additional Pharmacogenomic activities including the use for target
validation. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 








 WHEREAS, the parties desire to amend the Agreement effective as of January 1, 2003 to reflect the
foregoing. 
  
 NOW, THEREFORE, in consideration of the mutual
covenants and agreements contained herein, the parties hereto, intending to be legally bound, do hereby agree as follows: 
  
 The following amendments are to be incorporated into Appendix B: 
  
 1. Instead of a per screen price of [*****] in the Unit Price Section for Predictive Toxicogenomic Screens, the pricing will now be based on two portions: 
  
 1.1 [************************************************************************************************** 
 ******************************************************************************************************* 
 ****************************************************************************************************] 
  
 1.2 [************************************************************************************************** 
 ******************************************************************************************************* 
 ****************************************************************************************************] 
  
 2. The minimum level of all pharmacogenomic services in aggregate is [**********] per full
year of the Production Phase Term. No minimum level for the Predictive Toxicogenomics Screen is specified. 
  
 3. SNP Analysis Pricing: Due to the large variation in the number of exons per gene, the unit pricing for SNP Analysis is understood to analyze the SNPs across [*****] exons. 
  
 4. Miscellaneous: Except as amended hereby, the Agreement shall remain in full force and
effect. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original. 
  
 [Remainder of page intentionally left blank] 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 








 If the foregoing accurately sets forth our understanding, please so signify by signing and returning a duplicate copy of
this letter, whereupon this letter agreement shall take effect as an amendment to the Agreement. 
  

			
	Very truly yours,
	
	CuraGen Corporation
		
	By:	 	 /s/ Christopher K. McLeod

	 	 	

	 	 	 Name: Christopher K. McLeod

	 	 	 Title: Executive Vice President



  

			
	ACCEPTED AND AGREED:
	
	Bayer AG
		
	By:	 	 /s/ Dr. Karlsson

	 	 	

	 	 	 Name: Dr. Karlsson

	 	 	 Title: PH-R Head

		
	By:	 	 /s/ Dr. van den Kerckhoff

	 	 	

	 	 	 Name: Dr. van den Kerckhoff

	 	 	 Title: Patents and Licensing


  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.